Zydus gets USFDA nod for IBS-D drug
x
Zydus Lifesciences receives USFDA approval for Rifaximin Tablets, a generic treatment for Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults.
Photograph: Courtesy Zydus.
New Delhi, Jun 2 (PTI) Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.
Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.
Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Standard-Cap-Mkt
- 0.56 (+ 7.69)
- 7090777
- Spicejet
- 13.76 (+ 5.28)
- 7074832
- Vodafone-Idea
- 9.91 ( 0.00)
- 7010711
- Welcure-DrugandPharma
- 0.29 ( 0.00)
- 6414301
- Alstone-Textiles
- 0.14 ( 0.00)
- 6370104
MORE NEWS
© 2026 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback